SBRT for Prostate Cancer
Localized Prostate Cancer
Clinical AdoptionEvidence Generation & Promotion
Key Facts
Indication
Localized Prostate Cancer
Phase
Clinical Adoption
Status
Evidence Generation & Promotion
Company
About Accuray
Accuray is a publicly traded medical device company with a mission to expand the curative power of radiation therapy through precision and innovation. Founded in 1990, it has achieved a significant global footprint with its CyberKnife and Radixact systems installed in over 100 countries. The company's strategy centers on technological differentiation in robotic and helical radiotherapy, supported by integrated software and services, to address a broad spectrum of cancer cases from complex to common. It aims to improve patient quality of life by making treatments shorter, safer, and more effective.
View full company profileTherapeutic Areas
Other Localized Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Karolinska Institutet Prostate Cancer IRE Study | AngioDynamics | Randomized Controlled Trial |
| ORCA-010 | ORCA Therapeutics | Phase I/IIa |
| TULSA-PRO® | Profound Medical | Commercial |